VUITY Reports Strong Market Performance, Setting New Benchmark in Presbyopia Care | DelveInsight
DelveInsight's "VUITY Market Size, Forecast, and Market Insight Report" highlights the details around VUITY, which is a ...
DelveInsight Business Research, LLP: VUITY Reports Strong Market Performance, Setting New Benchmark in Presbyopia Care | DelveInsight
VUITY, an FDA-approved eye drop for presbyopia, has significant market potential given the growing aging population. With an estimated 128 million Americans affected by presbyopia, VUITY offers ...
pharmaphorum2d
Allergan builds case for first drug therapy for presbyopia
Now, there could be another alternative, in the form of eye drops administered daily, according to AbbVie's Allergan subsidiary, which reported new phase 3 data for its pilocarpine formulation ...
SpyGlass Pharma Appoints Chetan Pujara, Ph.D., as Chief Research & Development Officer
Dr. Pujara brings extensive industry experience to guide late-stage development of the SpyGlass Drug Delivery PlatformALISO VIEJO, Calif., March ...
Orange County Business Journal3d
FDA Greenlights Mazzo’s Neurotech Implant
The biotech company, focused on developing treatments for chronic eye conditions, received Food and Drug Administration (FDA) ...
pharmaphorum4d
Native American tribe open to more patent deals with pharma
The spokesperson added: “Allergan wants its patents to be enforced against infringers, (makers of generic eye drops) but in federal court, not in the IPR proceedings.” The tribe runs a large ...
Eye drops derived from PEDF protein slow vision loss in animal models
Researchers at the National Institutes of Health (NIH) have developed eye drops that extend vision in animal models of a ...
Science Daily6d
New eye drops slow vision loss in animals
Researchers have developed eye drops that extend vision in animal models of a group of inherited diseases that lead to progressive vision loss in humans, known as retinitis pigmentosa.